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ABSTRACT The complete amino acid sequence of the
mouse ,g chain from the BALB/c myeloma tumor MOPC 104Eis reported. The CA region contains four consecutive homology
regions of approximately 110 residues and a COOH-terminal
region of 19 residues. A comparison of this p chain from mouse
with a complete ;& sequence from human (Ou) and a partial A
chain sequence from dog (Moo) reveals a striking gradient of
increasing homology from the NH2-terminal to the COOH-ter-
minal portion of these It chains, with the former being the least
and the latter the most highly conserved. Four of the five sites
of carbohydrate attachment appear to be at identical residue
positions when the constant regions of the mouse and human
,g chains are compared. The , chain of MOPC 104E has a car-bohydrate moiety attached in the second hypervariable region.
This is particularly interesting in view of the fact that MOPC
104E binds a-l-'3)dextran, a simple carbohydrate. The
structural and functional constraints imposed by these com-
parative sequence analyses are discussed.
Immunoglobulins are comprised of two polypeptides, light (L)
and heavy (H) chains, and may be divided into five major
classes, IgM, IgG, IgA, IgD, and IgE, which are defined by their
corresponding heavy chains, ,t, y, ai, 6, and c, respectively. The
IgM molecule is the most primitive immunoglobulin in that it
is the first to appear in vertebrate evolution (1). Moreover, IgM
is the first immunoglobulin to appear during the ontogenetic
development of the immune system (2). Serological, immu-
nochemical, and evolutionary data suggest that IgM immu-
noglobulins have been more highly conserved than other classes
of immunoglobulins (1). For these reasons, the IgM molecule
is an excellent model protein for evolutionary analysis.
Each immunoglobulin chain is divided into an NH2-terminal
variable (V) region and a COOH-terminal constant (C) region.
The immunoglobulin polypeptides are divided into consecutive
homology regions approximately 110 residues in length. The
L chain has two homology regions and the human js chain has
five homology regions in addition to a COOH-terminal segment
composed of 19 residues (3). The basic unit of the immuno-
globulin molecule is two light and two heavy chains (H2L2), in
which pairs of homology regions fold together to form globular
domains. The L chain and the NH2-terminal portion of the H
chain generate two domains each, and the remaining COOH-
terminal regions of the two ;t chains fold into three domains.
From the NH2 to the COOH terminus of the , chain, these
domains are designated V, C/1, CA2, C.3, and CM4, respec-
tively.
The V domains recognize foreign structures (antigens) and
the C domains carry out a variety of effector functions that
ultimately lead to the destruction or elimination of foreign
antigens. The IgM molecule has at least three special effector
functions associated with its COOH-terminal domains. First,
the IgM molecule serves as a cell-surface receptor that can
trigger the progenitors of antibody-producing 13 cells to dif-
ferentiate upon interaction with complementary antigen (4).
Thus the IgM molecule can be an integral membrane protein
(5, 6), which is displayed on the membrane as a 7S monomer,
(2,2L2) (7, 8). Second, cells that have been stimulated to dif-
ferentiate into antibody-producing cells can secrete IgM mol-
ecules as 19S pentamers, (,u2L2)A, composed of 10 light and 10
heavy chains held together by a third type of polypeptide
designated the J chain (9). It is not known whether the mem-
brane-bound and secreted ,u chains have the same polypeptide
structure. Finally, after the IgM molecule binds antigen, the
C,4 domain activates the effector pathways of the complement
system (10).
In this paper we report the amino acid sequence of the se-
creted ,. chain derived from the mouse myeloma tumor MOPC
104E. The mouse ti chain is compared with a human ,u chain
whose sequence has been completely determined (11) and a dog
,q chain whose sequence has been partially determined (12, 13).
As previously observed when the human ,u sequence and the
dog At partial sequence were compared, there is a striking gra-
dient of sequence homology, with the COOH-terminal
homology regions significantly more conserved than the
NH2-terminal homology regions (12). Several structural features
of the ,u chain are highly conserved, including the placement
of disulfide bridges and the locations of tryptophan residues and
carbohydrate moieties in the constant region. The structure of
the secreted Ai chain places several interesting constraints on
the nature of the membrane-bound A chain of the IgM receptor
molecule.
MATERIALS AND METHODS
Isolation of ji Chain. The IgM-secreting tumor MOPC 104E
(,u, X) was grown intraperitoneally in (BALB/c X DBA/2) F1
mice. The IgM molecules were precipitated from ascites fluid
with ammonium sulfate and purified by gel filtration on a
column of ACA 22 (LKB). The purified IgM was completely
reduced with dithiothreitol and alkylated with iodoacetamide
in 6 M guanidine-HCl (14), and the heavy and light chains were
separated by gel filtration on a column of ACA 34 (LKB) in 3
M guanidine and 0.2 M ammonium bicarbonate. The complete
amino acid sequence of the X light chain of MOPC 104E has
been determined (15, 16).
Isolation of Cyanogen Bromide Fragments. Purified Ai
chains were cleaved with cyanogen bromide in 70% (wt/vol)
formic acid for 20-22 hr at 4VC (17). Cyanogen bromide pep-
tides were separated by gel filtration on a column of ACA 54
(LKB) in 3 M guanidine and 0.2 M ammonium bicarbonate.
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Protein and peptide purity was monitored at all stages of pu-
rification by electrophoresis in the presence of odium dt
sulfate on 10% or 18% polyacrylamide gels (18).
Compositional and Sequence Analysis. Amino acid com-
positions and carbohydrate analyses for amino sugars were
determined on samples hydrolyzed in 6 M HCl (1 10C for 24
hr and 3 hr, respectively) by using a Durrum D-500 amino acid
analyzer. Automated sequence analyses were performed on a
modified Beckman sequenator (19, 20). Samples were loaded
by using Polybrene (Aldrich), and phenylthiohydantoin de-
rivatives were identified by high-pressure liquid chromatog-
raphy (Waters Associates) as described (21).
Peptide Fragments. Fc fragments of IgM were prepared
according to the method of Shimizu et al. (22) and purified by
gel filtration on ACA 22 and ACA 34. Cyanogen bromide
peptides were succinylated (23) for trypsin digestion limited
to arginine residues. Cyanogen bromide peptides also were
cleaved at tryptophan residues by the procedure of Ozols et al.
(24). Smaller peptides were produced from cyanogen bromide
fragments by digestion with trypsin, chymotrypsin, and ther-
molysin. The resulting peptides were separated in two di-
mensions on paper by chromatography and high-voltage
electrophoresis (25) and where appropriate their amino acid
sequences were determined in the automated sequenator in the
presence of Polybrene (see ref. 21).
RESULTS
Sequence Strategy. The methionine residues of the MOPC
104E ,u chain were cleaved with cyanogen bromide and 10
peptides were isolated by gel filtration. The amino acid se-
quences of these peptides were determined at their NH2 termini
on the automatic sequenator. The sequences of selected peptides
produced by tryptophan, thermolysin, trypsin, and chymo-
trypsin cleavages also were determined to complete the primary
structure of each cyanogen bromide fragment. Fig. 1 sche-
matically illustrates the order of the cyanogen bromide frag-
ments. Only fragment CN1 was not isolated. Two cyanogen
bromide fragments that resulted from incomplete cleavage of
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the methionine residues at positions 20 (CN1-2) and 568(CNT44Y'v.'re isolated. Thus, cyanogen bromide fragments
covering the entire ,u chain have been obtained and their se-
quences have been completely determined.
The 10 methionine fragments of the mouse ,u chain can be
unambiguously aligned in a linear order without resorting to
homology comparisons with the human ,u chain. Sequence
analysis of the NH2-terminal 38 residues of the intact A chain
assigned cyanogen bromide fragments 1, 2, and 3, respectively,
to the NH2 terminus (Fig. 1). An Fc fragment, obtained by
trypsin digestion of the intact IgM in 5 M urea (22), shows that
the COOH-terminal sequence of CN5 and the NH2-terminal
sequence of CN6 are contiguous (Fig. 1). In addition, a cy-
anogen bromide digest of the Fc fragment yielded CN6, CN7,
and CN8-9. Because CN4 is not in the Fc fragment, it must
reside between CN3 and CN5 (Fig. 1). Because CN8-9 does not
have a COOH-terminal homoserine residue it must be the
COOH-terminal fragment. The only remaining fragment,
CN7, is then located between CN6 and CN8-9 (Fig. 1). These
assignments are supported by the previous isolation and se-
quence analysis of pepsin peptide fragments overlapping CN4
to CN5 and CN7 to CN8 (27). Thus direct sequence overlaps
are available for all methionine residues except those between
CN6-CN7 and CN3-CN4. There is the possibility that addi-
tional methionine fragments between CN3-CN4 and CN6-CN7
may have been lost in the isolation procedures. This possibility
appears unlikely because the mouse ,A chain in these two regions
can be aligned without sequence gaps against a completely
sequenced human g chain (Fig. 2).
Disulfide Bridges. The positions of the 14 cysteine residues
of the mouse ,u chain are indicated in Fig. 1. The assignments
of two disulfide bridges (residues 22 to 97; residues 153 to 213)
have been established through the isolation of cyanogen bro-
mide peptides from it chain with intact intrachain bridges
followed by analysis on reducing and nonreducing 18% poly-
acrylamide gels. In addition, the methionine fragments of the
Fc region, CN6, CN7, and CN8, are linked by intrachain di-
sulfide bridges. All 14 cysteine residues in the mouse ,u chain
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FIG. 1. Schematic drawing of the A heavy chain of IgM MOPC 104E showing (i) sites of cleavage by CNBr and the respective fragments(CN1 to CN9), (ii) the point of cleavage by trypsin in 5M urea giving the Fc fragment, (iii) the point of division of the variable (VH) and constant
(C,.) regions (3), (iv) the intrachain disulfide bridges, (v) the six homology regions (VH, C,1 to C,,4, C,. terminal), and (vi) the locations of the
six oligosaccharides (CHO 1 to CHO 6). The high-mannose oligosaccharides are circled and complex type oligosaccharides are boxed. Two oli-
gosaccharides are enclosed in broken lines to denote that the assignment of complex type was made from homology with the human ,.t oligosac-
charides (26). The linkages of three of the intrachain bridges are indicated by broken lines because they have been assigned only by assuming
homology with the human A sequence Ou (11). W indicates tryptophan residues. To facilitate homology comparisons, the scale corresponds
to the amino acid sequence positions of the human myeloma ,u chain Ou (11). Because there are a number of gaps and insertions between the
two sequences, the numbers indicating total amino acid residues in each 104E , chain fragment do not necessarily correspond to the numbers
obtained by counting the amino acid residues in the homologous Ou sequence.
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FIC. 2. The amino acid sequences of u chains from mouse MOPC 104E, human Ou (11), and canine Moo (12, 13). (The one-letter code for
amino acids is given in ref. 28.) Only the NH2-terminal and Fc sequences of the dog , chain are available. A straight line indicates identity with
the MOPC 104E sequence. Deletions are indicated by [1. The sites of carbohydrate attachment are boxed. Positions of carbohydrate attachment
have not been determined for the dog p chain. The homology unit boundaries have been assigned by an analysis of immunoglobulin three-di-
mensional structure as indicated in Table 1 (3). Three hypervariable regions (hv 1, hv 2, and hv 3) are indicated by arrows over appropriate V
region segments. Q* indicates pyrrolidone carboxylic acid.
are in positions homologous to the 14 cysteine residues of the
human it chain. Thus we assume the same cysteine residues will
be involved in interchain bridges and intradomain bridges as
indicated in Fig. 1. Accordingly, the cysteine residue at position
140 is probably bridged to the L chain and the cysteines at 337,
414, and 575 most likely form bridges with other A chains or
with the J chain (16, 29).
Oligosaccharide Assignments. The 104E A chain has six sites
of carbohydrate attachment, five in the constant region and one
in the variable region (Fig. 1). All six oligosaccharides contain
glucosamine and are attached to asparagine residues. The sites
of carbohydrate attachment were identified as blank cycles in
automatic sequenator runs. Subsequent enzymatic limit digests
of the carbohydrate-containing cyanogen bromide fragments
produced small peptides that were analyzed for the presence
of glucosamine. Four of the five C region oligosaccharides of
the mouse A chain are in positions identical to those of the
human u chain (Figs. 1 and 2). The fifth C region oligosac-
charide is attached to a nonhomologous position 31 residues
NH2-terminal to the site in Ou (positions 395 and 364 in human
and mouse, respectively).
DISCUSSION
The COOH-Terminal Portion of the CA Region Appears
More Highly ConservedThan the NH2-TerminalPortion. In
Fig. 2 the complete sequence of the ,u chains of mouse and
human are listed along with the V region and Fc sequence data
from the dog p chain. Several insertions, deletions, and sequence
inversions, some of which may be technical artifacts in analysis
(28), are noted in comparing these sequences. Using the criteria
of Beale and Feinstein (3), we have identified in the mouse CM,
as in its human counterpart, four homology regions of ap-
proximately 110 residues and an additional COOH-terminal
region 19 residues in length (Fig. 2). The mouse p chain, like
the human p chain, has no hinge region separating any of the
C region domains (3).
Two amino acid residues, cysteine and tryptophan, are highly
conserved in the CA, regions (Figs. 1 and 2). All 12 cysteine
residues are conserved in the mouse and human C. regions, as
are the 8 that can be compared in the dog sequence. The mouse
C. region has six tryptophan residues, each of which is ho-
mologous to one of the seven tryptophan residues in the human
C. region (Fig. 2). All five tryptophans in the partial sequence
of the dog C., region are in the same positions as their mouse and
human counterparts. In contrast, the human and mouse C,
regions have six and five methionine residues, respectively, only
two of which are conserved. Because of their conservation, it
is reasonable to conclude that cysteine and tryptophan residues
play an important role in the domain structure of immuno-
globulins.
Table 1 is a compilation of the homology comparisons be-
tween the various homology regions of mouse, human, and dog.
There is a striking gradient of homology from the NH2-terminal
to the COOH-terminal region. The C. 1 homology unit of
mouse shows 48% homology with human ,u as contrasted with
78% and 89% homologies in the C,4 and the COOH-terminal
regions, respectively. The existence of sequence gaps in the
NH2-terminal homology regions (two in C,1 and three in C,2)
but not in the COOH-terminal homology regions of the A chain
(Fig. 2) suggests that the NH2-terminal regions have diverged
more. Thus, the COOH-terminal portion of the p chain is sig-
nificantly more conserved than the NH2-terminal portion. If
individual domains do carry out separate functions, these ob-
servations imply that there are strong selective constraints on
2934 Immunology: Kehry et al.
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The p chains were divided into four homology units and a COOH-terminal region according to an analysis of the three-
dimensional structures of several immunoglobulins not of the , class: CH1 = residues 127-232; CH2 = residues 233-339;
CH3 = residues 340-446; CH4 = residues 447-557; and C terminus = residues 558-576 (3). Sequence gaps (deletions or in-
sertions) are not counted in homology comparisons. In the lower right of the square for each region and comparison is listed
the number of amino acids compared in the homology calculation divided by the total number of amino acids in that homology
unit. The number of sequence identities in each unit was used to calculate the percent homology, which is given in the upper
left of each square.
the more COOH-terminal domains. These constraints may be
related to the requirements for the polymerization of pentamers
in the secreted IgM molecule, the structural requirements im-
posed on an integral membrane receptor with regard to
membrane attachment and the triggering of differentiation,
or the activation of the complement pathway, which has been
localized to theC,,4 domain (10).
Sites of Carbohydrate Attachment to the C, Region Are
Similar in Human and Mouse ,u Chains. The ,u chain of mouse
has five sites of carbohydrate attachment in the constant region
(Fig. 1). Four of these five carbohydrate attachment sites are
at identical positions in the mouse and human (26) CA, regions(Fig. 2). The carbohydrate moiety on residue 171 is of the
complex type and those on residues 402 and 563 are of the
high-mannose type (W. J. Grimes, personal communication),
in agreement with the carbohydrate types on the human
chain (26). Compositional analyses on the remaining two oli-
gosaccharides are not yet complete. Each carbohydrate moiety
is attached to the asparagine residue of a three-residue recog-
nition sequence, -Asn-X-Ser/Thr, in which X may be any amino
acid and Ser/Thr indicates either serine or threonine. Substi-
tution of a methionine for a serine at position 397 in mouse ,u
has eliminated the recognition sequence for the carbohydrate
attachment site at position 395 in human ,u. In the mouse u
chain we find a carbohydrate moiety at residue 364, where
there exists a carbohydrate recognition sequence that is absent
in the dog and human , chains. Other recognition sequences
that are apparently not glycosylated also occur in the Au chain(74-76 in human Ou, 263-265 and 347-349 in mouse MOPC
104E). Thus, the elimination and formation of an attachment
site implies either that this region of the protein is on the exterior
of the molecule and is therefore accessible to glycosylating
enzymes or that a carbohydrate moiety is required (structurally,
functionally, or both) in this region of the u chain.
The carbohydrate moieties of human and mouse ,u chains are
present in the CA,1, CA2, and C.3 domains as well as the
COOH-terminal region-(Figs. 1 and 2). A variety of functions
have been suggested for the carbohydrate on heavy chains,
including the solubilization of the heavy chain, the facilitation
of the secretory process, the promotion of the assembly of
pentamers, and the contribution of structural features for a
variety of specific effector functions (26, 30-34). Whatever their
function, the conservation of the locations of carbohydrate at-
tachment during the 75 million years that mouse and human
C,, genes have diverged from one another suggests that strong
selective forces are maintaining the recognition sequences.
The V Domain of MOPC 104E, an a-1--3)Dextran
Binder, Has a Carbohydrate Moiety in Its Antigen-Binding
Site. A carbohydrate moiety has been identified at asparagine
57, which lies in the middle of the second hypervariable region
of the MOPC 104E ji chain. There are several unusual features
of the V region carbohydrate site. First, the usual recognition
sequence is missing; this high-mannose carbohydrate moiety
is attached to the asparagine of an Asn-Gly-Gly-Thr sequence.
Although the majority of asparagine-linked carbohydrate
moieties are associated with a recognition sequence, the se-
quence is clearly not an absolute requirement for the attach-
ment of carbohydrate to asparagine residues (35). Second, the
IgM molecule secreted by the MOPC 104E tumor binds a
simple carbohydrate, a-(1-3)-dextran (36). Thus, we have
localized a carbohydrate moiety to the antigen-binding site of
the heavy chain of an immunoglobulin that binds a defined
hapten. This observation raises the possibility that carbohy-
drate-carbohydrate interactions may constitute a portion of
the binding energy for the hapten, a-(1-3)-dextran. In view
of what we know about the specificities of protein and carbo-
hydrate interactions, however, this possibility appears unlikely
(37). Third, a second myeloma protein, J558(a, A), which also
binds a-(1-o3)-dextran, appears to have a carbohydrate moiety
at precisely the same position (unpublished observations). It is
likely that this carbohydrate moiety also occurs in the heavy
chains of normally induced serum antibodies to a-(1-3)-
dextran (unpublished observations). The role, if any, for car-
bohydrate in the V domains of immunoglobulins remains an
interesting, but unanswered question.
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Structure of the u Chain Places Constraints on the IgM
Molecule as an Integral Membrane Receptor. The mono-
meric IgM molecule is an integral membrane protein that serves
as a cell-surface receptor for antigen on B cells that can trigger
the B cells to differentiate into antibody-producing cells (4). The
membrane (m) and secreted (s) IgM molecules are serologically
crossreactive, implying that they share structural features or
may even be identical. Conflicting data suggest both that the
COOH terminal portion of the A.m chain is identical to yu (38)
and that these regions are different (39).
If the Aum and /us chains are identical in amino acid sequence,
the Mm chain cannot be transmembrane in its orientation. The
a-helix is the most stable polypeptide secondary structure
within a membrane (40, 41). This configuration requires about
21 uncharged residues to span the membrane. Alternatively,
the extended : configuration requires two paired stretches of
9 uncharged amino acids to span the membrane. We have
compared the three mammalian ii chains over their COOH-
terminal two homology units, which presumably contain the
site of membrane attachment. The longest sequence of un-
charged amino acids in any of these molecules is 14 residues in
length (positions 469-482 in the human and dog M chains) (Fig.
2). However, the mouse it chain has a charged lysine residue
at position 477, reducing the stretch of uncharged amino acids
in this region to 8 residues. In addition, this region contains a
cysteine at position 474 that is presumably joined to cysteine-
536 to form the CA4 intradomain disulfide bridge. If one as-
sumes that all mammals will attach their ji chains to membranes
in a similar fashion, there is no uncharged sequence shared by
the COOH-terminal regions of the mouse, human, or dog M
chains that could span the membrane in either the a-helical or
the extended unpaired f3 configuration (41, 42). We conclude
that, if the tinm and Ms chains are identical, the IgM molecule
cannot be a transmembrane protein that meets the above
specifications. Moreover, tyrosine-labeling experiments on
inside-out vesicles are consistent with the supposition that the
IgM molecule is not transmembrane (43). If the Mm chain is not
a transmembrane polypeptide, then the IgM molecule may
associate with the membrane by virtue of a specific receptor
molecule, an association analogous to the interaction of IgE with
its membrane receptor on mast cells (44). In this regard, both
IgM and IgE have an additional constant region domain when
compared with IgG and IgA molecules (3).
We have preliminary evidence that suggests the Mm and As
chains differ in their primary amino acid sequences. Any pri-
mary structural differences could be generated by mRNA
splicing mechanisms, posttranslational proteolysis, or the oc-
currence of duplicated M chains genes. It is possible to determine
the chemical structure of Mm and define precisely the rela-
tionship between Am and As chains. Moreover, we have isolated
a genomic M clone, whose nucleotide sequence can be deter-
mined. Such studies should allow us to distinguish unambigu-
ously among the three models for Mm and Mts expression cited
above.
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